Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:74:154211.
doi: 10.1016/j.jcrc.2022.154211. Epub 2023 Jan 9.

Transient diabetes insipidus in critically ill COVID19 patients

Liran Statlender  1 , Guy Fishman  2 , Moran Hellerman  2 , Ilya Kagan  2 , Itai Bendavid  2 , Dan Gorfil  3 , Shani Kaptzon  3 , Pierre Singer  2
Affiliations
Review

Transient diabetes insipidus in critically ill COVID19 patients

Liran Statlender et al. J Crit Care. 2023 Apr.

Abstract

Purpose: Vasopressin has become an important vasopressor drug while treating a critically ill patient to maintain adequate mean arterial pressure. Diabetes insipidus (DI) is a rare syndrome characterized by the excretion of a large volume of diluted urine, inappropriate for water homeostasis. We noticed that several COVID19 patients developed excessive polyuria suggestive of DI, with a concomitant plasma sodium-level increase and/or low urine osmolality. We noticed a temporal relationship between vasopressin treatment cessation and polyuria periods. We reviewed those cases to better describe this phenomenon.

Methods: We retrospectively collected COVID19 ECMO patients' (from July 6, 2020, to November 30, 2021) data from the electronic medical records. By examining urine output, urine osmolality (if applicable), plasma sodium level, and plasma osmolality, we set DI diagnosis. We described the clinical course of DI episodes and compared baseline characteristics between patients who developed DI and those who did not.

Results: Out of 37 patients, 12 had 18 episodes of DI. These patients were 7 years younger and had lower severity scores (APACHE-II and SOFA). Mortality difference was not seen between groups. 17 episodes occurred after vasopressin discontinuation; 14 episodes were treated with vasopressin reinstitution. DI lasted for a median of 21 h, with a median increase of 14 mEq/L of sodium.

Conclusions: Temporary DI prevalence after vasopressin discontinuation in COVID19 ECMO patients might be higher than previously described for vasopressin-treated patients.

Keywords: COVID19; Diabetes insipidus (DI); ECMO; Polyuria; Vasopressin.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest There are no conflicts of interest.

References

    1. Hammond D.A., Ficek O.A., Painter J.T., McCain K., Cullen J., Brotherton A.L., et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy. 2018 May;38(5):531–538. - PubMed
    1. Hammond D.A., Cullen J., Painter J.T., McCain K., Clem O.A., Brotherton A.L., et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med. 2019 Nov;34(11–12):910–916. - PubMed
    1. Russell J.A., Walley K.R., Singer J., Gordon A.C., Hébert P.C., Cooper D.J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008 Feb 28;358(9):877–887. - PubMed
    1. Sharshar T., Carlier R., Blanchard A., Feydy A., Gray F., Paillard M., et al. Depletion of neurohypophyseal content of vasopressin in septic shock*. Crit Care Med. 2002 Mar;30(3):497–500. - PubMed
    1. Landry D.W., Levin H.R., Gallant E.M., Ashton R.C., Seo S., D’Alessandro D., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997 Mar 4;95(5):1122–1125. - PubMed